PIRS vs. KZR, CASI, LEXX, EQ, KRON, DARE, CLNN, NBRV, NXTC, and OCUP
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Equillium (EQ), Kronos Bio (KRON), Daré Bioscience (DARE), Clene (CLNN), Nabriva Therapeutics (NBRV), NextCure (NXTC), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Pieris Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Pieris Pharmaceuticals received 144 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 61.37% of users gave Pieris Pharmaceuticals an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
In the previous week, Pieris Pharmaceuticals and Pieris Pharmaceuticals both had 2 articles in the media. Kezar Life Sciences' average media sentiment score of 0.94 beat Pieris Pharmaceuticals' score of 0.44 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
Kezar Life Sciences has a consensus target price of $11.00, indicating a potential upside of 1,485.01%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Pieris Pharmaceuticals.
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Kezar Life Sciences has a net margin of 0.00% compared to Pieris Pharmaceuticals' net margin of -39.71%. Kezar Life Sciences' return on equity of -47.28% beat Pieris Pharmaceuticals' return on equity.
Pieris Pharmaceuticals has higher revenue and earnings than Kezar Life Sciences. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Kezar Life Sciences beats Pieris Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
